PHARMACTION: what changed
Position among the sector peers
Sector benchmark: create a free account or sign in to use this tool.
You see every sector peer as a dot per ratio, with the company in two financial years and every ratio over five years against the sector.
What moved between 2024 and 2025
Largest movements
- Receivables within one year +€44,431
up €44,431 (+18.6%), from €239,034 to €283,465
of which Trade receivables: +€41,427
- Cash -€23,988
down €23,988 (-80.2%), from €29,904 to €5,916
mainly Receivables within one year (-€44,431) and Trade debts (-€10,216)
- Profit (loss) carried forward +€19,582
up €19,582 (+41.7%), from €46,968 to €66,549
- Trade debts -€10,216
down €10,216 (-5.2%), from €198,362 to €188,147
- Advances received +€8,424
new in 2025: €8,424
- Gross operating margin +€5,881
up €5,881 (+26.2%), from €22,478 to €28,360
- Taxes +€1,632
up €1,632 (+28.6%), from €5,716 to €7,348
- Depreciation +€492
up €492 (+96.8%), from €508 to €1,000
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €271,430 | €290,873 | +€19,442 | +7.2% |
| Fixed assets | 21/28 | €2,492 | €1,492 | -€1,000 | -40.1% |
| Intangible fixed assets | 21 | €2,492 | €1,492 | -€1,000 | -40.1% |
| Current assets | 29/58 | €268,939 | €289,381 | +€20,442 | +7.6% |
| Amounts receivable within one year | 40/41 | €239,034 | €283,465 | +€44,431 | +18.6% |
| Trade receivables | 40 | €236,465 | €277,892 | +€41,427 | +17.5% |
| Other amounts receivable | 41 | €2,569 | €5,573 | +€3,004 | +117% |
| Cash at bank and in hand | 54/58 | €29,904 | €5,916 | -€23,988 | -80.2% |
| Total equity and liabilities | 10/49 | €271,430 | €290,873 | +€19,442 | +7.2% |
| Equity | 10/15 | €67,373 | €86,954 | +€19,582 | +29.1% |
| Contributions | 10/11 | €20,405 | €20,405 | = | 0.0% |
| Profit (loss) carried forward | 14 | €46,968 | €66,549 | +€19,582 | +41.7% |
| Amounts payable | 17/49 | €204,058 | €203,918 | -€140 | -0.1% |
| Amounts payable within one year | 42/48 | €204,058 | €203,918 | -€140 | -0.1% |
| Trade debts | 44 | €198,362 | €188,147 | -€10,216 | -5.2% |
| Suppliers | 440/4 | €198,362 | €188,147 | -€10,216 | -5.2% |
| Advances received on contracts in progress | 46 | - | €8,424 | +€8,424 | |
| Taxes, remuneration and social security | 45 | €5,695 | €7,348 | +€1,652 | +29.0% |
| Taxes | 450/3 | €5,695 | €7,348 | +€1,652 | +29.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €508 | €1,000 | +€492 | +96.8% |
| Other operating charges | 640/8 | €384 | €387 | +€3 | +0.8% |
| Gross operating margin | 9900 | €22,478 | €28,360 | +€5,881 | +26.2% |
| Operating profit (loss) | 9901 | €21,586 | €26,973 | +€5,387 | +25.0% |
| Financial income | 75/76B | - | €1 | +€1 | |
| Recurring financial income | 75 | - | €1 | +€1 | |
| Financial charges | 65/66B | €35 | €44 | +€9 | +24.7% |
| Recurring financial charges | 65 | €35 | €44 | +€9 | +24.7% |
| Profit (loss) for the period before taxes | 9903 | €21,551 | €26,930 | +€5,379 | +25.0% |
| Income taxes | 67/77 | €5,716 | €7,348 | +€1,632 | +28.6% |
| Profit (loss) for the period | 9904 | €15,835 | €19,582 | +€3,747 | +23.7% |
| Profit (loss) for the period to be appropriated | 9905 | €15,835 | €19,582 | +€3,747 | +23.7% |
Value
latest balance sheet 30-06-2025 · indication, not a valuation or adviceIndicative value of the equity
Indication, not a valuation or adviceMidpoint €111,035 · 50% capitalised earnings, 50% adjusted equity
Capitalisation rate 12% result over 3 years, excluding non-recurring income and charges earnings weight 50% revaluation €0 other adjustment €0 EBITDA multiple
The filed figures and these assumptions give no positive value. The adjusted equity and the average result are both zero or negative.
Part of the calculation comes out below zero. A shareholding is never worth less than zero, so the floor is zero.
Adjusted equity
- Equity (10/15)
- €86,954
- Formation expenses (20)
- €0
- Intangible fixed assets (21)
- -€1,492
- Revaluation of assets
- €0
- Deferred tax on the revaluation
- €0
- Other adjustment
- €0
- Adjusted equity
- €85,463
Capitalised earnings
- 2025
- €19,582
- 2024
- €15,835
- 2023
- €13,762
- 2022
- €9,363
- excluding non-recurring income and charges
- €9,400
- 2021
- €9,295
- Average result, excluding non-recurring income and charges
- €16,393
- Divided by the capitalisation rate
- 14% / 12% / 10%
- Capitalised earnings
- €117,093 / €136,608 / €163,930
Your EBITDA multiple
- EBITDA 2025
- €27,972
- Net financial debt
- -€5,916
- Your multiple
- -
- Value with your multiple
- -
These accounts do not break down the debts after one year. They count in full as financial debt.
Limits of the indication
- Checked holds no market prices or comparable transactions.
- Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
- Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
- The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.
For a valuation to base a decision on, go to a company auditor or a certified accountant.
Next steps
Calculation and sources
Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 30 June 2024 and 30 June 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 9 November 2026 via checked.be.